SUPPLEMENT ARTICLE |

* Department Psychiatry, Childrens Hospital Boston and Harvard Medical School, Boston, Massachusetts
Childrens Hospital of Los Angeles, Los Angeles, California
| ABSTRACT |
|---|
|
|
|---|
Methods. In this prospective, longitudinal study, 228 children who were born to mothers with treated PKU or untreated mild hyperphenylalaninemia were compared with 70 control subjects at 7 years of age.
Results. Offspring cognitive outcome negatively correlated with the number of gestational weeks that elapsed until maternal metabolic control was achieved (r = 0.61). Behavioral outcome was similarly affected. Postnatal measurement of stimulation in the home was also related to offspring IQ.
Conclusions. Children who are born to mothers who have PKU and attain metabolic control before or very early in pregnancy seem to begin life with undiminished potential. Delay in attainment of maternal metabolic control is associated with declines in offspring developmental outcome. The postnatal environment also significantly affects outcome. Interventions to improve dietary compliance before and throughout pregnancy as well as interventions to improve the postnatal home environment may reduce the risks associated with maternal PKU.
Key Words: maternal phenylketonuria maternal PKU cognitive outcome behavioral outcome
Abbreviations: Phe, phenylalanine PKU, phenylketonuria MHP, mild hyperphenylalaninemia HPA, hyperphenylalaninemia
The present study includes school-age assessments of cognitive development, motor skills, expressive and receptive language, attention, daily living skills, achievement, emotional well-being, and behavior. Environmental influences such as prenatal exposure to elevated phenylalanine (Phe) levels, maternal IQ, maternal age, socioeconomic position, and stimulation in the home were considered.
| METHODS |
|---|
|
|
|---|
|
Procedures
A network of psychologists performed the majority of evaluations, usually in the homes of the participants. Data collection procedures have been described previously.1
Analyses
The hyperphenylalaninemia (HPA) sample was divided according to timing of maternal metabolic control, defined as the number of gestational weeks after which blood Phe levels remained consistently <600 µmol/L throughout the remainder of the pregnancy. When sample size permitted, analyses were also performed with the more stringent definition of maternal metabolic control as maintenance of blood Phe levels between 120 and 360 µmol/L.
Analyses were performed using STATA 6.0.2 Pearson correlation analysis was used to evaluate the relationship of maternal demographic and treatment factors to offspring outcome, when normal distributions were confirmed. Analysis of variance was used to compare continuous outcome variables among the various maternal Phe-control subgroups, with Dunnetts method for pairwise comparisons of each subgroup to control subjects. Multiple logistic regression analyses were performed to investigate predictors of categorical outcomes. Nonparametric methods such as rank sum tests, Wilcoxon tests, and Fisher exact tests were used, as needed, for categorical outcomes or when continuous variables deviated from normality. When multiple comparisons were made among subgroups, Bonferroni adjustment was applied to P values.
| RESULTS |
|---|
|
|
|---|
|
|
As noted in Table 4, maternal age, socioeconomic status, and IQ at enrollment were lower in the HPA groups compared with controls. There was considerable variability in the postnatal environments provided by the women in the HPA group. The percentage of women who attained scores in the lowest quartile on the Home Observation for Measurement of the Environment (HOME) Scale10 was significantly greater for women who attained metabolic control after 10 weeks (P < .001) compared with control subjects. Women who attained metabolic control after 10 weeks gestation were more likely to be single than women in the control group (P < .001). As determined by logistic regression analyses (Table 5), mothers who attained metabolic control after 10 weeks gestation (using the 600-µmol/L cutoff) were >4 times as likely to be <21 years of age (P = .02), twice as likely to have an IQ <85, and 3.5 times as likely to be single (P = .001).
|
|
| DISCUSSION |
|---|
|
|
|---|
Offspring of women with untreated MHP performed similarly to control subjects. At 7 years of age, only 1 child who was born to a mother with untreated MHP evidenced signs of mental retardation, and 14% had severe behavior problems. In the control group, 1 child performed in the range of mental retardation and 23% had severe behavior problems.
Offspring of optimally treated women who had PKU and attained metabolic control before conception did not differ from control children. This held true when maternal blood Phe levels remained between 120 and 600 µmol/L as well as when levels were between 120 and 360 µmol/L. These optimally treated children scored higher on cognitive and behavioral tests than offspring of treated women who attained metabolic control after pregnancy began but before 10 weeks gestation, although this difference was not statistically significant.
Approximately 16% of treated women with HPA attained metabolic control between 10 and 20 weeks gestation. The developmental outlook for their offspring varied, with 73% of children performing within the average intellectual range at 7 years of age but 27% performing in the borderline range and 7% performing in the range of mental retardation. Language deficits and academic difficulties were also more frequent.
Assessments obtained when the children were 7 years of age indicated that weaknesses in language were present as well as weaknesses in other developmental domains. A recent study comparing maternal PKU offspring with children with PKU and control subjects confirmed these findings and suggested an increased risk among maternal PKU offspring for executive function deficits and attention-deficit/hyperactivity disorder.11
Despite a highly significant correlation between maternal metabolic control and offspring outcome, exceptions to the rule frequently occurred. Some children who were born to poorly treated women developed normally, and some children who were born to very well-treated mothers experienced mental retardation. Heterogeneity might be attributable to differences in timing and level of exposure. The impact of a relatively low level of exposure over a long period of time may not be comparable to the impact of high levels over a short period of time.12 Heterogeneity might also reflect genetic differences in mothers.13
These findings point to the primacy of maternal metabolic control during pregnancy in predicting offspring outcome, yet postnatal factors cannot be ignored. All but a few of the women who were enrolled in the study had terminated the diet during middle childhood and resumed treatment only for purposes of pregnancy. The vast majority discontinued treatment as soon as the infant was born. Elevated Phe levels, associated with reductions in cognitive abilities, depression, anxiety, and other emotional difficulties,14 may have compromised their parenting abilities. In the present study, the median maternal IQ among women with HPA was 85 (range: 40130) compared with 101 (range: 79126) for control subjects (z = 6.57, P < .0001). Significantly more women with PKU experienced lower socioeconomic conditions. These factors, associated with less stimulation in the home, increased the risk for a low IQ in the offspring.
In the general population, heritability of IQ is in the 0.40 to 0.50 range,15 and the correlation between child IQ and socioeconomic status is approximately 0.30.16 In this study, the correlation of HPA offspring IQ with maternal IQ was 0.41 and with socioeconomic status was 0.48. In the literature, additional variance in child IQ can be explained when other risk factors are added to the equation (including biological influences, multiple moves, single-parent families, deaths, loss of employment, and other stresses).17,18 This suggests that cumulative risk contributes more significantly to eventual outcome than single-risk factors. This is particularly true in maternal PKU, for which risk factors include the biological risk of elevated exposure to Phe in utero plus low maternal IQ, low socioeconomic status, and a lack of stimulation in the home. Offspring outcome, therefore, may differ because of idiosyncratic combinations of genetic and environmental factors in each child.19 The analogy of signal-to-noise applies: "The signal of early medical and biological influences on outcome is gradually obscured by the noise generated by the environment."15
Only longer-term follow-up can determine whether maternal PKU offspring will grow up to "love and work." For children whose mothers attained metabolic control after 20 weeks gestation, the outlook seems bleak, and for those whose mothers attained metabolic control between 10 and 20 weeks gestation, the outlook is mixed. Many of these children experience difficulties communicating, delays in development, poor academic achievement, and serious behavior problems that potentially limit social relationships and ability to secure employment. Children who are born to mothers who attain metabolic control before or very early in pregnancy seem to begin life with undiminished potential. However, they face environmental risks associated with their mothers PKU. Interventions and research focused on these factors may be most productive in reducing adverse outcomes in maternal PKU.
| ACKNOWLEDGMENTS |
|---|
The following psychologists are gratefully acknowledged for assistance in developing the study protocol and collecting data: Pi-Nian Chang, PhD; Sanja Cipcic-Schmidt, Dipl-Psych; Ramona Hall, MS; Felicia Travis, PhD; Alan Stern, PhD; and Jo Nanson, PhD.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Maillot, M. Lilburn, J. Baudin, D. W Morley, and P. J Lee Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine Am. J. Clinical Nutrition, September 1, 2008; 88(3): 700 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
Committee on Genetics Maternal Phenylketonuria Pediatrics, August 1, 2008; 122(2): 445 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Koch, C. Azen, E. Friedman, W. Hanley, H. Levy, R. Matalon, B. Rouse, F. Trefz, J. Ning, and F. de la Cruz Research Design, Organization, and Sample Characteristics of the Maternal PKU Collaborative Study Pediatrics, December 1, 2003; 112(6): 1519 - 1522. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||